References
1. Kiivet R.A. Pharmaceutical Registration in Estonia. The Regulatory Affairs Journal, 1993, 4, No 11: 902-906
2. Kiivet R.A., Bergman U. and Sjöqvist F. The Use of Drugs in Estonia Compared to the Nordic Countries. European Journal of Clinical Pharmacology, 1992, 42: 511-515
3. Rägo L. National Drug Policy. Pharmaceutical Reform in Estonia. WHO Essential Drug Monitor, 1994, 17: 10
4. Rägo L. Estonias National Drug Regulatory Structure Finalized. NLN News, 1994, 1:2-3
5. The IFPMA Compendium on Regulation of Pharmaceuticals for Human Use, 1994, Edition, Volume 1.
6. Rägo L. Regulatory Affairs in Estonia. The Regulatory Affairs Journal, 1994, Vol. 5, 12: 1004-1009
7. Rägo L. Approval Systems for Pharmaceuticals: Estonia. NLN Baltic Conference 1994, 1995, NLN Publication (Uppsala), 37: 60-69
8. Rägo L. Pharmaceutical Inspection in Estonia. NLN Baltic Conference 1995, 1995, NLN Publication (Uppsala), 39: 39-44
9. Rägo L. Description of the reimbursement system in Estonia. NLN Baltic Conference 1996, NLN Publication (Uppsala), 42: 53-56
10. Rägo L. Pricing Principles and price levels in Estonia. NLN Baltic Conference 1996, NLN Publication (Uppsala), 42: 91-93
11. Rägo L. Description of the reimbursement system in Estonia. NLN Baltic Conference 1996, NLN Publication (Uppsala), 42: 53-56
12. Rägo L. Pharmaceutical Inspections in Estonia. The Regulatory Affairs Journal, 1997, Vol. 8, 4: 248-251
13. Rägo L. The Estonian Drug Market. NLN Baltic Conference 1997, NLN Publication (Uppsala), 44: 29-30
14. Kiivet R.A. Drug Utilization in the Baltic States. NLN Baltic Conference 1997, NLN Publication (Uppsala), 44: 45-49
15. Uusküla M., Raudsepp K. Non-commercial drug information and monitoring of commercial drug information in Estonia. NLN Baltic Conference 1997, NLN Publication (Uppsala), 44: 93-98
16. Tamm S. Estonia embraces the idea of self-medication, OTC Bulletin, Sept. 25, 1998: 14-16
17. Rägo L. An update of the regulatory affairs in Estonia. NLN Baltic Conference 1998, NLN Publication (Uppsala), 49: 19-24
18. Kiivet R.A. How to facilitate the conduct of clinical trials in the Baltic region. NLN Baltic Conference 1998, NLN Publication (Uppsala), 49: 65-68
19. Imelik H.. Clinical use of blood products. NLN Publication (Uppsala) 1998, 48: 9-23
20. Raudsepp K. Extension of EU approvals to the CADREAC countries. NLN Publication (Uppsala) 1999, 51: 19-23
21. Estonian State Agency of Medicines. Regulatory Affairs Journal October 2000, 10: 793
22. Ööpik T. Information activities at the Estonian State Agency of Medicines. NLN Seminar 2000, NLN Publication (Uppsala), 54: 29-32
23. Estonian State Agency of Medicines. Regulatory Affairs Journal August 2001, 8: 254
24. Rootslane L., Irs A. ATC/DDD methodology: a country perspective. WHO Drug Information Vol. 15, No. 1, 2001: 26-30
25. Irs A., Rootslane L. The use of antihypertensive drugs in Estonia compared to the Nordic Countries. Pharmacology and Toxicology Vol. 89, supp I, 2001: 50
Results